UK Regulator Probes McCormick-Unilever Foods Deal, Adding Near-Term Divestiture Risk

What happened

Unilever's planned sale of a majority of its foods business to McCormick & Company faces an investigation by the UK's Competition and Markets Authority, the regulator said Wednesday. The probe will assess whether the deal could reduce competition in UK markets, potentially delaying completion. This divestiture aligns with Unilever's Growth Action Plan 2030 to focus on its 30 Power Brands in Beauty & Wellbeing and Personal Care, but the sale is a complex transaction that could face remedies or outright blockage. The master report notes Unilever is already early in a major transformation, including the Ice Cream demerger, and this additional regulatory hurdle heightens near-term execution risk. Nonetheless, the company's core cash generation and balance sheet remain strong, with the stock trading at a premium to intrinsic value.

Implication

Long-term, if the deal is blocked or significantly delayed, Unilever would retain a lower-growth, lower-margin business that it intended to exit, diluting the portfolio transformation and potentially delaying capital reallocation to higher-return areas. However, the company's diversified portfolio and strong free cash flow provide resilience, and the valuation gap to intrinsic value remains the primary driver of the potential sell rating, not this regulatory event.

Thesis delta

The thesis gains a minor negative catalyst: UK competition scrutiny could delay the divestment of the foods business, adding to the list of execution risks already highlighted. This does not alter the fundamental value assessment, which remains dominated by the stock's rich valuation relative to DCF, but it reinforces the need for a wider margin of safety. Investors should monitor the outcome of the probe for any change in deal terms or timeline.